Recent Advances in Peptide Inhibitors Targeting Wild-Type Ras Protein Interactions in Cancer Therapy
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26041425 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Weirong Qin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical College, Guangxi Medical University, Nanning 530021, China. Hauptthemen laut MEDLINE: Neoplasms, ras Proteins, Peptides, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fund of the Natural Science Foundation of Guangxi Province, Fund of Natural Science Foundation of China grants, Scientific Research Fund of Guangxi Education Department.
Abstract (Originalsprache)
Ras proteins are pivotal in the regulation of cell proliferation signals, and their dysregulation is intricately linked to the pathogenesis of various malignancies. Peptide inhibitors hold distinct advantages in targeting Ras proteins, attributable to their extensive binding domains, which result from the smooth surfaces of the proteins. The array of specific strategies includes the employment of full hydrocarbon chains, cyclic peptides, linear peptides, and N-terminal nucleation polypeptides. These methods effectively suppress the Ras signaling pathway through distinct mechanisms, highlighting their potential as anti-neoplastic agents. Moreover, cutting-edge methodologies, including the N-terminal aspartate nucleation strategy and the utilization of hydrocarbon-stapled peptides, are transforming the landscape of therapeutics aimed at Ras proteins. These innovations highlight the promise of peptide libraries and combinatorial chemistry in augmenting binding affinity, specificity, and cellular permeability, which are pivotal for the development of potent anti-cancer agents. The incorporation of dual therapeutic strategies, such as the synergy between peptide inhibitors and conventional chemotherapy or the use of radiotherapy enhancers, emerges as a compelling strategy to bolster the efficacy of cancer treatments targeting the Ras-MAPK pathway. Furthermore, recent studies have demonstrated that Ras-targeting stabilized peptides can amplify the radio-sensitivity of cancer cells, offering an innovative approach to enhance the efficacy of radiation therapy within cancer management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical College, Guangxi Medical University, Nanning 530021, China.
- Guangxi Key Laboratory of Bioactive Molecules Research and Evaluation, Guangxi Medical University, Nanning 530021, China.
- Key Laboratory of Biological Molecular Medicine Research (Guangxi Medical University), Education Department of Guangxi Zhuang Autonomous Region, Nanning 530021, China.
- State Key Laboratory of Chemical Oncogenomics, Guangdong Provincial Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen 518055, China.
ORCID-Profile: Weirong Qin, Jin Huang
Förderung
- Fund of the Natural Science Foundation of Guangxi Province
- Fund of Natural Science Foundation of China grants
- Scientific Research Fund of Guangxi Education Department
- Guangxi Science and Technology Major Program
- First-class discipline innovation-driven talent program of Guangxi Medical University
- The first batch of universal support policies for young talents in Guangxi Zhuang Autonomous Region
- Key Laboratory of Biological Molecular Medicine Research
- Research Ability Improvement Project of Guangxi Higher Education
Zitieren
APA
Qin, W., Liu, Z., Huang, M., Liang, L., Gan, Y., Huang, Z., Huang, J., & Wei, X. (2025). Recent Advances in Peptide Inhibitors Targeting Wild-Type Ras Protein Interactions in Cancer Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26041425
Vancouver
Qin W, Liu Z, Huang M, Liang L, Gan Y, Huang Z, et al. Recent Advances in Peptide Inhibitors Targeting Wild-Type Ras Protein Interactions in Cancer Therapy. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26041425
BibTeX
@article{Qin2025,
author = {Qin, Weirong and Liu, Zijian and Huang, Mingyu and Liang, Lin and Gan, Yuxin and Huang, Zubei and Huang, Jin and Wei, Xiangzan},
title = {Recent Advances in Peptide Inhibitors Targeting Wild-Type Ras Protein Interactions in Cancer Therapy},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26041425}
}
EUVIMED